Literature DB >> 6103853

Somatostatin concentration responds to arginine in portal plasma: effects of fasting, streptozotocin diabetes, and insulin administration in diabetic rats.

T Kazumi, M Utsumi, G Yoshino, K Ishihara, Y Hirose, H Makimura, S Baba.   

Abstract

Changes of somatostatin concentration in response to a single i.v. injection of arginine (400 mg/kg body weight) were examined in extracted portal plasma of normal and diabetic rats in the fully fed state and after 24 h or fasting, as well as in diabetic rats treated with insulin for one week. In both normal and diabetic animals fasted for 24 h, the basal level of somatostatin declined but the magnitude of the arginine-induced elevation of somatostatin was not affected, suggesting a physiologic role of the tetradecapeptide in nutrient homeostasis. When compared with intact rats, diabetic animals were shown to have increased levels of somatostatin before and after arginine administration, both of which were attenuated by insulin replacement therapy. These findings suggest that alterations of D cell function in streptozotocin diabetes may be related to either insulin deficiency or its metabolic consequences.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6103853     DOI: 10.2337/diab.29.1.71

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  8 in total

Review 1.  Secretion of somatostatin from the normal and diabetic pancreas. Studies in vitro.

Authors:  K Hermansen
Journal:  Diabetologia       Date:  1980       Impact factor: 10.122

2.  Protective role of superoxide dismutase against diabetogenic drugs.

Authors:  S E Gandy; M G Buse; R K Crouch
Journal:  J Clin Invest       Date:  1982-09       Impact factor: 14.808

3.  Acute effects of alloxan- and streptozotocin-induced insulin deficiency on somatostatin and glucagon secretion by the perfused isolated rat pancreatico-duodenal preparation.

Authors:  Y Goto; M Berelowitz; L A Frohman
Journal:  Diabetologia       Date:  1981       Impact factor: 10.122

4.  Contribution of the pancreas to circulating somatostatin-like immunoreactivity in the normal dog.

Authors:  G J Taborsky; J W Ensinck
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

5.  Pancreatic immunoreactive somatostatin and diabetes mellitus.

Authors:  A Ertan; A Arimura; K Akdamar; T Shibata; K Groot; M Luciano; F J Mather; H Degertekin; N Agrawal; J Ryan
Journal:  Dig Dis Sci       Date:  1984-07       Impact factor: 3.199

6.  Comparison of somatostatin distribution in pancreatic duct ligated rats and streptozotocin diabetic rats.

Authors:  W Lee; H Wakasugi; H Ibayashi
Journal:  Gastroenterol Jpn       Date:  1983-10

7.  Somatostatin inhibits rat hepatic T4-5'-deiodinase. The effect is independent of the associated hypoinsulinemia.

Authors:  L A Gavin; M Moeller
Journal:  J Clin Invest       Date:  1983-12       Impact factor: 14.808

8.  Biosynthesis and release of thyrotropin-releasing hormone immunoreactivity in rat pancreatic islets in organ culture. Effects of age, glucose, and streptozotocin.

Authors:  L O Dolva; J H Nielsen; B S Welinder; K F Hanssen
Journal:  J Clin Invest       Date:  1983-12       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.